Our previous study also suggested the potential efficacy of certain ICIs [cytotoxic T-lymphocyte associated protein 4 (CTLA4) and Hepatitis A virus cellular receptor 2 (HAVCR2) inhibitors] in CRC with MSI [6]. This evidence concerns the gene CTLA4 and colorectal carcinoma.